[Special Stock] EV Suseong, US 'Triple Demic' Spread... Respiratory Infectious Diseases 99% Eliminated, Kobixil US Sales Up

[Asia Economy Reporter Jang Hyowon] EV Suseong is showing strong performance amid the spread of the triple-demic in the United States. The nationwide sales of 'Kovixil,' which is effective not only against COVID-19 but also all respiratory infectious diseases, appear to be highlighted.

As of 9:50 AM on the 26th, EV Suseong is trading at 1,705 KRW, up 55 KRW (3.33%) from the previous trading day.

As winter approaches, warning signals of a 'Triple-demic' are sounding in the U.S. This is due to the emergence of new COVID-19 variants including BQ.1 and BQ.1.1, as well as influenza (flu) and respiratory syncytial virus (RSV) infections showing signs of an outbreak.

According to the New York Times (NYT) on the 23rd (local time), the number of flu cases in the U.S. has increased earlier than usual and is expected to surge rapidly over the next few weeks.

Additionally, the number of children infected with RSV, which shows symptoms similar to flu and COVID-19, has sharply increased over the past month. In some states, the surge in RSV patients has led to a shortage of pediatric and adolescent hospital beds.

The new COVID-19 variants including BQ.1 and BQ.1.1 are also spreading. The most recent booster vaccines released by Pfizer and Moderna target the BA.5 variant and are reported not to be effective against the currently spreading viruses.

On this day, Salbacion announced that it has started selling Kovixil in the U.S., following the UK and Latin America. Initially, it will be distributed to offline pharmacies in the U.S., and from next month, when supply increases, the product is expected to be available for purchase on global online malls.

Kovixil is the world's first product approved by government agencies that simultaneously satisfies prevention efficacy against COVID-19 and the common cold. This product has proven its effectiveness against COVID-19 and the safety of spray use through clinical trials in the U.S. It has also demonstrated over 99% neutralizing power against various respiratory viruses including cold influenza viruses and RSV.

Recently, EV Suseong announced that its management rights will be acquired by Salbacion. After securing management rights of EV Suseong, Salbacion plans to promote joint business and proceed with exclusive online distribution contracts in major Asian countries including Japan.

This content was produced with the assistance of AI translation services.